Constellation Pharmaceuticals has appointed Jigar Raythatha as president and CEO. He will lead the company focused on harnessing its deep scientific expertise in cancer epigenetics, to advance two ongoing clinical programs, CPI-1205 and CPI-0610, targeting EZH2 and BET, respectively.
Prior to rejoining Constellation, Raythatha served as chief business officer at Jounce Therapeutics. He was the first employee at Jounce and helped build the company from its inception to a publicly-traded 100-person research and development organization. Previously, he served as head of corporate development at Constellation where he led business development, strategy, and program management functions. Earlier in his career, Raythatha held roles of increasing responsibility at Biogen, Red Abbey Venture Partners, and A.T. Kearney. He earned a Master of Business Administration from Columbia University and a Bachelor of Arts in biochemistry and economics from Rutgers University.
Raythatha said that he is pleased to return to Constellation at a time when the company is poised for breakout success. The team has done a fantastic job driving multiple clinical programs through Phase 1, and I look forward to working with everyone here to build on this progress and translate the company’s stellar science into meaningful outcomes for cancer patients.